Dr. Aric Logsdon Joins Psycheceutical Bioscience, Inc. as Company’s Scientific Director
MIAMI, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatments, today announced the addition of Dr. Aric Logsdon as the company's Scientific Director.
- MIAMI, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatments, today announced the addition of Dr. Aric Logsdon as the company's Scientific Director.
- "As a medical community, we remain largely without treatments for neuropsychiatric and neurocognitive disorders, including post-traumatic stress disorder and dementia.
- Psychedelics have profound effects on the human brain which are still poorly understood, said Dr. Aric Logsdon, Scientific Director of Psycheceutical.
- "We are excited to have Dr. Logsdon join our team of expert technologists and mental health science experts," said Chad Harman, CEO of Psycheceutical.